Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
AFP2d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Yahoo Finance3d
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The biotech has many more tricks up its sleeves. It recently earned approval for its next-gen cystic fibrosis (CF) therapy, Alyftrek. Vertex has a monopoly in the CF drug market. Alyftrek is yet ...
pharmaphorum4d
FDA approves flurry of drugs ahead of holiday season
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the SKYLINE 102 and SKYLINE 103 trials, which showed that Alyftrek matched ...
Zacks.com on MSN5d
The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics
T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.
Nasdaq5d
The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics
Vertex is preparing for two potential near-term launches — suzetrigine in acute pain and vanza triple in CF in 2025. Vanza triple was approved as Alyftrek in December. It is rapidly progressing ...
LinkedIn3d
Computer Bob Emmelkamp’s Post
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis https://lnkd.in/gAEHw-XJ ...